Palisade Bio, Inc. (PALI): R&D Expense
$10.19M
Year ended 2025-12-31
$21.36M
Trailing 12 months to 2026-06-30
+15.9%
3-year compound annual growth
+26.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.19M | +12.5% | 2026-03-20, From 2025-01-01 |
| 2024-12-31 | $9.06M | +31.5% | 2026-03-20, From 2024-01-01 |
| 2023-12-31 | $6.89M | +5.3% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $6.55M | +169.4% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $2.43M | -21.6% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $3.10M | n/a | 2022-03-17, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $10.19M | +12.5% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
Compare PALI, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗